The potential benefits of TrumpRx may be modest, according to independent analyses of the newly launched website.
The portal, introduced by the Trump administration earlier this year, is designed to address rising drug costs by connecting consumers with manufacturer-sponsored discounts on prescription medications. The site aggregates available offers from a small group of pharmaceutical companies, allowing users to search for medications and access pricing programs directly.
Early reviews of the site by organizations including the Kaiser Family Foundation (KFF) and the Center for American Progress (CAP) found that many of the medications listed already had discount programs available prior to the portal's launch. In some cases, lower-cost generic alternatives were already widely accessible, potentially limiting the incremental savings offered through the platform.
According to CAP, as of March 16, TrumpRx lists just 54 drugs, a fraction of the roughly 24,000 medications approved by the Food and Drug Administration for use in the United States. Of those 54 drugs, roughly 31% already have generic equivalents available at lower cost, and more than half of the remaining medications can be found at comparable or cheaper prices through existing discount platforms such as GoodRx. After accounting for prices already available through manufacturer coupons and patient assistance programs, only a single drug on the platform — Cetrotide, a fertility medication — offers a genuinely new lower price. Several commonly used medications — including Insulin Lispro, Farxiga and Amjevita — were unchanged in price, while others such as Ovidrel, Incruse Ellipta and Relenza were higher through TrumpRx than previously available options, CAP said.
TrumpRx is restricted to cash-paying patients, and the program's coupons cannot be combined with insurance. Nearly half of uninsured Americans never reach the point of receiving a prescription, a requirement for using TrumpRx. According to a KFF analysis, nearly 46.6% of uninsured adults ages 18 to 64 reported not seeing a doctor or other health professional in 2023. Applied to the estimated 27.9 million adults without insurance in 2026, this means approximately 13 million Americans will never reach the most basic prerequisite for using TrumpRx, the report said.
The launch comes amid a broader healthcare affordability crisis. According to KFF, Americans paid a record $98 billion out-of-pocket for prescription drugs in 2024, a 25% increase over five years. By 2025, nearly 42% of Americans reported being prescribed a medication they could not afford, and one in five skipped a prescription due to cost. The burden falls hardest on uninsured adults, with about one-quarter saying they rationed their medications that year, compared with 14% of insured adults.
Meanwhile, roughly 22 million Affordable Care Act marketplace enrollees could see premium payments increase significantly if enhanced federal tax credits expire, KFF said.
© Arc, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to TMSalesOperations@arc-network.com. For more information visit Asset & Logo Licensing.